



"Biomarkers" in medical imaging are the key to detecting and treating cancer

Press Release

MEDIAN Technologies Joins Forces with Quintiles to Provide World-Class Clinical Trial Imaging Services

Strategic agreement to leverage MEDIAN's advanced lesion management system (LMS) software applications and associated clinical trial imaging services for early, late-stage or post-approval oncology clinical trials

SOPHIA ANTIPOLIS, France – February 16, 2012 – To improve the assessment of how cancer patients are responding to investigational therapies in clinical trials, MEDIAN Technologies (ALMDT) today announced a strategic agreement with Quintiles to offer advanced integrated image services to biopharmaceutical customers worldwide.

The agreement with Median, a leading services provider for image interpretation and management in oncology clinical trials, is designed to further strengthen Quintiles' full range of services to accelerate oncology drug development. With Quintiles, the world's leading biopharmaceutical services provider, as its partner, Median can extend the reach of its technologies in the clinical development field to benefit customers globally.

"This collaboration will result in better quality of data, increased awareness for biopharma for go/no-go decisions along the drug development stages, and ultimately more robust regulatory submission to health agencies," said MEDIAN Chief Executive Officer Fredrik Brag.

Under terms of the agreement, Quintiles will have the potential to be awarded warrants, which if exercised could amount to up to a 15% equity position in the company.

Anne Pilling, Vice President, Quintiles Oncology Therapeutic Delivery Unit, said: *"This partnership complements Quintiles' current portfolio of imaging solutions and provides further proof of our commitment to provide biopharma and healthcare service providers with the tools, expertise and services needed to increase productivity and better the lives of patients."*

Images are essential in clinical trials and are used at all steps of cancer care, from patient diagnosis to monitoring. In clinical trials, they provide a critical indication of patient response to treatment of new candidate drug and are used as input for new drug and therapeutic schemes registration. MEDIAN's solution addresses two critical imaging challenges: data variability amongst readers and efficient management of the imaging data workflow.



"Biomarkers" in medical imaging are the key to detecting and treating cancer

About Quintiles: Quintiles is the only fully integrated biopharmaceutical services company offering [clinical](#), [commercial](#), [consulting](#) and [capital](#) solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: Based in Sophia Antipolis, MEDIAN was founded in 2002 by Fredrik Brag (Current CEO), Gérard Milhiet and Arnaud Butzbach. The company has a staff of 40, over half of whom work in R&D, and has a subsidiary in the USA.

MEDIAN Technologies offers solutions and services for diagnosing and monitoring cancer patients for clinical trials market in oncology, its priority market, and the patient care market. MEDIAN collaborated with institutes at the cutting edge of medical imaging, among which the French National Institute for Computer Science and Control (INRIA), Chicago University and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL).

MEDIAN Technologies has been present in the market since 2007 through direct and indirect sales of its LMS solutions and alliances with specialist cancer centers in Europe and the USA.

For more information on MEDIAN, please visit: www.mediantechologies.com

CONTACTS QUINTILES

Quintiles Media Relations

Jay Johnson
+1 919 993 2066
jay.johnson@quintiles.com

Quintiles Investor Relations

Greg Connors
+1 919 998 2000
invest@quintiles.com

CONTACTS MEDIAN

MEDIAN Technologies

Fredrik Brag, CEO
+33 492 906 582
fredrik.brag@mediantechnologies.com

Press

ALIZE RP
Caroline Carmagnol
+ 33 664 189 959
+ 33 142 688 643
caroline@alizerp.com

Investors

ACTIFIN
Anaïs de Scitivaux
+ 33 1 56 88 11 14
adescitivaux@actifin.fr

Anne-Sophie Cosquéric
+ 33 1 42 68 86 41
anne-sophie@alizerp.com